Literature DB >> 14615479

Liver disintegration in the mouse embryo caused by deficiency in the RNA-editing enzyme ADAR1.

Jochen C Hartner1, Carolin Schmittwolf, Andreas Kispert, Albrecht M Müller, Miyoko Higuchi, Peter H Seeburg.   

Abstract

ADAR1 (adenosine deaminase acting on RNA-1) is widely expressed in mammals, but its biological role is unknown. We show here by gene targeting that ADAR1 selectively edits in vivo two of five closely spaced adenosines in the serotonin 5-hydroxytryptamine subtype 2C receptor pre-mRNA of nervous tissue; and hence, site-selective adenosine-to-inosine editing is indeed a function of ADAR1. Remarkably, homozygosity for two different null alleles of ADAR1 caused a consistent embryonic phenotype appearing early at embryonic day 11 and leading to death between embryonic days 11.5 and 12.5. This phenotype manifests a rapidly disintegrating liver structure, along with severe defects in definitive hematopoiesis, encompassing both erythroid and myeloid/granuloid progenitors as well as spleen colony-forming activity from the aorta-gonad-mesonephros region and fetal liver. Probably as a consequence of these developmental impairments, ADAR1-deficient embryonic stem cells failed to contribute to liver, bone marrow, spleen, thymus, and blood in adult chimeric mice. Thus, ADAR1 subserves critical steps in developing non-nervous tissue, which are likely to include transcript editing.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14615479     DOI: 10.1074/jbc.M311347200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  229 in total

1.  Host response to polyomavirus infection is modulated by RNA adenosine deaminase ADAR1 but not by ADAR2.

Authors:  Cyril X George; Charles E Samuel
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Serotonin 2c receptor RNA editing in major depression and suicide.

Authors:  Rebecca Lyddon; Andrew J Dwork; Mehdi Keddache; Larry J Siever; Stella Dracheva
Journal:  World J Biol Psychiatry       Date:  2012-03-09       Impact factor: 4.132

Review 3.  Activity regulation of adenosine deaminases acting on RNA (ADARs).

Authors:  Cesare Orlandi; Alessandro Barbon; Sergio Barlati
Journal:  Mol Neurobiol       Date:  2011-11-20       Impact factor: 5.590

Review 4.  Substitutional A-to-I RNA editing.

Authors:  Bjorn-Erik Wulff; Kazuko Nishikura
Journal:  Wiley Interdiscip Rev RNA       Date:  2010 Jul-Aug       Impact factor: 9.957

5.  RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself.

Authors:  Brian J Liddicoat; Robert Piskol; Alistair M Chalk; Gokul Ramaswami; Miyoko Higuchi; Jochen C Hartner; Jin Billy Li; Peter H Seeburg; Carl R Walkley
Journal:  Science       Date:  2015-07-23       Impact factor: 47.728

Review 6.  Adenosine deaminases acting on RNA, RNA editing, and interferon action.

Authors:  Cyril X George; Zhenji Gan; Yong Liu; Charles E Samuel
Journal:  J Interferon Cytokine Res       Date:  2010-12-23       Impact factor: 2.607

Review 7.  A-to-I RNA editing and human disease.

Authors:  Stefan Maas; Yukio Kawahara; Kristen M Tamburro; Kazuko Nishikura
Journal:  RNA Biol       Date:  2006-01-12       Impact factor: 4.652

8.  ADAR1 RNA deaminase limits short interfering RNA efficacy in mammalian cells.

Authors:  Weidong Yang; Qingde Wang; Kelly L Howell; Joshua T Lee; Dan-Sung C Cho; John M Murray; Kazuko Nishikura
Journal:  J Biol Chem       Date:  2004-11-19       Impact factor: 5.157

9.  Altered RNA editing in mice lacking ADAR2 autoregulation.

Authors:  Yi Feng; Christopher L Sansam; Minati Singh; Ronald B Emeson
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

10.  Human ADAR1 Prevents Endogenous RNA from Triggering Translational Shutdown.

Authors:  Hachung Chung; Jorg J A Calis; Xianfang Wu; Tony Sun; Yingpu Yu; Stephanie L Sarbanes; Viet Loan Dao Thi; Abigail R Shilvock; H-Heinrich Hoffmann; Brad R Rosenberg; Charles M Rice
Journal:  Cell       Date:  2018-01-25       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.